Kranzler HR, Feinn R, Morris P, Hartwell EE. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction 2019;114:septiembre. [Ref.ID 103238]

Simó Miñana J. Guerras médicas: a propósito del ensayo EXCEL . Salud, dinero y atención primaria 2019:15 de diciembre. [Ref.ID 103225]

Hermida RC, Crespo JJ, Domínguez-Sardina M, et al.. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2019:septiembre. [Ref.ID 103201]

Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen RJ, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394:24 de octubre. [Ref.ID 103199]

Anónimo. Outbreak of lung injury associated with e-cigarette use, or vaping. CDC 2019:3 de octubre. [Ref.ID 103188]

Korol S, White M, O'Meara E, Rouleau JL, White-Guay B, Dorais M, Ahmed A, de Denus S, Perreault S. Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?. Eur J Clin Pharmacol 2019;75:837-47. [Ref.ID 103176]

Young K. No evidence haloperidol helps in hospital delirium. Journal Watch 2019:3 de septiembre. [Ref.ID 103168]

Finnerub NB. Nonnarcotic methods of pain management. N Engl J Med 2019;380:20 de junio. [Ref.ID 103139]

Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, Oprescu AM, Salsitz E. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial. Am J Psychiatry 2019:21 de mayo. [Ref.ID 103125]

Haight BR, Learned SM, Lafont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Linq W, Heidbreder C, RB-US-13-0001 Study Investigators. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019;393:23 de febrero. [Ref.ID 103111]

Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues A, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow C-M, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology 2019:6 de marzo. [Ref.ID 103052]

Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103035]

Jones G. GW Pharma's cannabis-based medicine to be tested in dementia. PMLiVE 2019:1. [Ref.ID 103025]

Taylor P. Finch’s microbiota drug for C. diff gets FDA breakthrough status. PMLiVE 2019:11 de febrero. [Ref.ID 103019]

Attia E, Steinglass JE, Walsh BT, Wang Y, Wu P, Schreyer C, Wildes J, Yilmaz Z, Guarda AS, Kaplan AS, Marcus MD. Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial. Am J Psychiatry 2019:18 de enero. [Ref.ID 103015]

Young K. Diabetes guidelines updated. Journal Watch 2018:1. [Ref.ID 102893]

Girard TD , Exline MC , Carson SS , Hough CL , Rock P , Gong MN , Douglas IS , Malhotra A , Owens RL , Feinstein DJ , Khan B , Pisani MA , Hyzy RC , Schmidt GA , Schweickert WD , Hite RD , Bowton DL , Masica AL , Thompson JL , Chandrasekhar R , Pun BT , Strength C , Boehm LM , Jackson JC , Pandharipande PP , Brummel NE , Hughes CG , Patel MB , Stollings JL , Bernard GR , Dittus RS , Ely EW , for the MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in vritical illness. N Engl J Med 2018;379:22 de octubre. [Ref.ID 102838]

Chapman KR, Hurst JR, Frent SM, Larbiq M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018;198:1 de agosto. [Ref.ID 102826]

Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ 2018;362:k2693. [Ref.ID 102821]

Meltzer AC, Burrows PK, Wolfson AB, Hollander JE, Kurz M, Kirkali Z, Kusek JW, Mufarrij P, Jackman SV, Brown J. Effect of tamsulosin on passage of symptomatic ureteral stones. A randomized clinical trial. JAMA Intern Med 2018;178:1051-7. [Ref.ID 102775]